Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS)

NCT02979899 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.

NCT NCT02979899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02979899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS)
Lead sponsor
Tracon Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 13, 2017
Completion date
August 31, 2019
Enrollment
128 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

advanced angiosarcoma